BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19864234)

  • 21. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
    Tousková M; Maisnar V; Krejsek J; Kopecký O
    Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration.
    Nadav L; Katz BZ; Baron S; Yossipov L; Polliack A; Deutsch V; Geiger B; Naparstek E
    Br J Haematol; 2006 Jun; 133(5):530-2. PubMed ID: 16681641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
    van Velzen JF; van den Blink D; Bloem AC
    Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response.
    Demyanets S; Kaider A; Simonitsch-Klupp I; Bayer G; Subasic A; Thalhammer R; Esterbauer H; Krauth MT; Agis H; Reiter T; Schwarzinger I
    Ann Hematol; 2020 Nov; 99(11):2599-2609. PubMed ID: 32935190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
    Petrella T; Bagot M; Willemze R; Beylot-Barry M; Vergier B; Delaunay M; Meijer CJ; Courville P; Joly P; Grange F; De Muret A; Machet L; Dompmartin A; Bosq J; Durlach A; Bernard P; Dalac S; Dechelotte P; D'Incan M; Wechsler J; Teitell MA
    Am J Clin Pathol; 2005 May; 123(5):662-75. PubMed ID: 15981806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).
    Hundemer M; Klein U; Hose D; Raab MS; Cremer FW; Jauch A; Benner A; Heiss C; Moos M; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Dec; 40(11):1033-7. PubMed ID: 17891186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
    Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
    Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry.
    Bozzi F; Gambirasio F; Luksch R; Collini P; Brando B; Fossati-Bellani F
    Anticancer Res; 2006; 26(5A):3281-7. PubMed ID: 17094441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
    Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
    Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistological analysis in diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD38-positive plasma cells.
    Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Nishiwaki U; Masuda Y; Hiraoka N; Takayama A; Nishimura Y; Tsuji M; Hanafusa T
    Hematology; 2012 Nov; 17(6):317-20. PubMed ID: 23168070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin.
    Matsuo Y; Drexler HG; Harashima A; Okochi A; Hasegawa A; Kojima K; Orita K
    Leuk Res; 2004 Aug; 28(8):869-77. PubMed ID: 15203285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.
    Narita K; Kobayashi H; Abe Y; Kitadate H; Takeuchi M; Matsue K
    Int J Hematol; 2018 Oct; 108(4):371-374. PubMed ID: 29978432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
    Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32).
    Buonaccorsi JN; Kroft SH; Harrington AM; VanTuinen P; Olteanu H
    Ann Diagn Pathol; 2011 Dec; 15(6):385-8. PubMed ID: 21724429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm.
    Hwang K; Park CJ; Jang S; Chi HS; Huh JR; Lee JH; Suh C; Lee KH
    Histopathology; 2013 Apr; 62(5):764-70. PubMed ID: 23470050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.